Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1702664rdf:typepubmed:Citationlld:pubmed
pubmed-article:1702664lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:1702664lifeskim:mentionsumls-concept:C0003402lld:lifeskim
pubmed-article:1702664lifeskim:mentionsumls-concept:C0000854lld:lifeskim
pubmed-article:1702664lifeskim:mentionsumls-concept:C0017822lld:lifeskim
pubmed-article:1702664lifeskim:mentionsumls-concept:C0036581lld:lifeskim
pubmed-article:1702664lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:1702664lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1702664lifeskim:mentionsumls-concept:C0444956lld:lifeskim
pubmed-article:1702664lifeskim:mentionsumls-concept:C1515075lld:lifeskim
pubmed-article:1702664lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:1702664pubmed:issue2lld:pubmed
pubmed-article:1702664pubmed:dateCreated1991-2-20lld:pubmed
pubmed-article:1702664pubmed:abstractTextHigh-dose antioxidant supplementation has recently been recommended for multiple sclerosis (MS) patients. This study tests the clinical safety, the glutathione peroxidase (GSH-px) activity, and the absorption of selenium during such supplementation. Eighteen MS patients were given 6 tablets especially made for this study, equivalent to 6 mg sodium selenite, 2 g vitamin C, and 480 mg vitamin E a day for five wk. GSH-px, which was lower than in non-MS controls before the start of treatment, increased fivefold during 5 wk of treatment. Side effects were scarce. Ten MS patients were subjected to a 24-h selenium absorption study after ingestion of 2 active tablets, equivalent to 2 mg sodium selenite. Selenium, which was low initially, increased 24% during the first 3 h and then stabilized. It is concluded that the tested antioxidant treatment seems to be safe and that MS patients have low GSH-px, which may be increased by the tested antioxidant treatment.lld:pubmed
pubmed-article:1702664pubmed:languageenglld:pubmed
pubmed-article:1702664pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1702664pubmed:citationSubsetIMlld:pubmed
pubmed-article:1702664pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1702664pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1702664pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1702664pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1702664pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1702664pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1702664pubmed:statusMEDLINElld:pubmed
pubmed-article:1702664pubmed:monthFeblld:pubmed
pubmed-article:1702664pubmed:issn0163-4984lld:pubmed
pubmed-article:1702664pubmed:authorpubmed-author:SørensenP SPSlld:pubmed
pubmed-article:1702664pubmed:authorpubmed-author:HansenJ CJClld:pubmed
pubmed-article:1702664pubmed:authorpubmed-author:MaiJJlld:pubmed
pubmed-article:1702664pubmed:issnTypePrintlld:pubmed
pubmed-article:1702664pubmed:volume24lld:pubmed
pubmed-article:1702664pubmed:ownerNLMlld:pubmed
pubmed-article:1702664pubmed:authorsCompleteYlld:pubmed
pubmed-article:1702664pubmed:pagination109-17lld:pubmed
pubmed-article:1702664pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:meshHeadingpubmed-meshheading:1702664-...lld:pubmed
pubmed-article:1702664pubmed:year1990lld:pubmed
pubmed-article:1702664pubmed:articleTitleHigh dose antioxidant supplementation to MS patients. Effects on glutathione peroxidase, clinical safety, and absorption of selenium.lld:pubmed
pubmed-article:1702664pubmed:affiliationDepartment of Neurology, Arhus Kommunehospital, Denmark.lld:pubmed
pubmed-article:1702664pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1702664pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed